Don’t miss the latest developments in business and finance.

Lupin drops despite impressive Q1 performance

Image
Capital Market
Last Updated : Aug 09 2016 | 2:47 PM IST

Lupin was down 3.01% to Rs 1,641.85 at 14:31 IST on BSE, amid intraday volatility after consolidated net profit rose 55.1% to Rs 882 crore on 40% growth in net sales to Rs 4313.60 crore in Q1 June 2016 over Q1 June 2015.

The result was announced during market hours today, 9 August 2016.

Meanwhile, the S&P BSE Sensex was down 94.46 points or 0.34% at 28,088.11.

On BSE, so far 5.06 lakh shares were traded in the counter as against average daily volume of 1.22 lakh shares in the past one quarter. The stock was highly volatile. The stock lost as much as 4.17% at the day's low of Rs 1,622 so far during the day. The stock rose as much as 2.17% at the day's high of Rs 1,729.50 so far during the day. The stock had hit a record high of Rs 2,127 on 6 October 2015. The stock had hit a 52-week low of Rs 1,294.05 on 29 March 2016. The stock had underperformed the market over the past one month till 8 August 2016, advancing 3.39% compared with 3.89% rise in the Sensex. The scrip had also underperformed the market in past one quarter, gaining 6.69% as against Sensex's 11.71% rise.

The large-cap company has equity capital of Rs 90.20 crore. Face value per share is Rs 2.

Lupin's Managing Director Nilesh Gupta said that the company has delivered its best results to date in tune with its growth momentum. This was a record quarter, driven by robust growth across all key markets for the company viz. the United States, India and Japan, he said. The management remains committed to maintaining the company's growth trajectory given new product launches and approvals driven by strategic investments in technology and research, Gupta said.

Lupin is a pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The company is a significant player in the cardiovascular, diabetology, asthma, pediatric, CNS, GI, anti-infective and NSAID space and holds global leadership positions in the anti-TB segment.

Powered by Capital Market - Live News

Also Read

First Published: Aug 09 2016 | 2:26 PM IST

Next Story